As noted in Table 1, BRAF inhibitors and BRAF inhibitors + mitogen-activated protein kinase (MAPK; MEK) inhibitors (both are MAPK pathway inhibitors) provide improved survival for patients with metastatic melanoma with BRAF gene mutations. This evidence concerns the gene MAP2K7 and metastatic melanoma.